The role of nitric oxide on visual-evoked potentials in MPTP-induced Parkinsonism in mice

[1]  J. Duarte,et al.  Pesticides exposure as etiological factors of Parkinson's disease and other neurodegenerative diseases--a mechanistic approach. , 2014, Toxicology letters.

[2]  C. Maximino,et al.  Nitric oxide as a regulatory molecule in the processing of the visual stimulus. , 2014, Nitric oxide : biology and chemistry.

[3]  Eberhard O Voit,et al.  Rotenone and paraquat perturb dopamine metabolism: A computational analysis of pesticide toxicity. , 2014, Toxicology.

[4]  Oliver Schmachtenberg,et al.  Nitric oxide signaling in the retina: What have we learned in two decades? , 2012, Brain Research.

[5]  P. Jenner,et al.  The effect of nNOS inhibitors on toxin-induced cell death in dopaminergic cell lines depends on the extent of enzyme expression , 2011, Brain Research.

[6]  G. Tanriover,et al.  The Effect of Docosahexaenoic Acid on Visual Evoked Potentials in a Mouse Model of Parkinson’s Disease: The Role of Cyclooxygenase-2 and Nuclear Factor Kappa-B , 2011, Neurotoxicity Research.

[7]  Guy C. Brown,et al.  Nitric oxide and neuronal death. , 2010, Nitric oxide : biology and chemistry.

[8]  M. Zusso,et al.  alpha-Synuclein- and MPTP-generated rodent models of Parkinson's disease and the study of extracellular striatal dopamine dynamics: a microdialysis approach. , 2010, CNS and Neurological Disorders - Drug Targets.

[9]  Ji-Jie Pang,et al.  Light responses and morphology of bNOS‐immunoreactive neurons in the mouse retina , 2010, The Journal of comparative neurology.

[10]  M. Lehner,et al.  Inhibition of inducible nitric oxide synthase in respiratory diseases. , 2009, Biochemical Society transactions.

[11]  D. Zhu,et al.  Neuronal nitric oxide synthase: structure, subcellular localization, regulation, and clinical implications. , 2009, Nitric oxide : biology and chemistry.

[12]  E. Esposito,et al.  Involvement of Nitric Oxide in Nigrostriatal Dopaminergic System Degeneration , 2009, Annals of the New York Academy of Sciences.

[13]  J C Rothwell,et al.  Physiology and Anatomy of Possible Oscillators in the Central Nervous System , 2008, Movement disorders : official journal of the Movement Disorder Society.

[14]  E. Bézard,et al.  Protective Effects of Green Tea Polyphenols in the 6-OHDA Rat Model of Parkinson’s Disease Through Inhibition of ROS-NO Pathway , 2007, Biological Psychiatry.

[15]  L. Soulère,et al.  An expeditious synthesis of 4-hydroxy-2E-nonenal (4-HNE), its dimethyl acetal and of related compounds. , 2007, Chemistry and physics of lipids.

[16]  Y. Boo,et al.  An improved method to measure nitrate/nitrite with an NO-selective electrochemical sensor. , 2007, Nitric oxide : biology and chemistry.

[17]  J. Andersen,et al.  Oxidative stress in neurodegeneration: cause or consequence? , 2004, Nature Reviews Neuroscience.

[18]  Neal S. Peachey,et al.  Electrophysiological analysis of visual function in mutant mice , 2003, Documenta Ophthalmologica.

[19]  T. Wichmann,et al.  Pathophysiology of Parkinson's Disease: The MPTP Primate Model of the Human Disorder , 2003, Annals of the New York Academy of Sciences.

[20]  S. Przedborski,et al.  Nitric Oxide and Reactive Oxygen Species in Parkinson's Disease , 2003, IUBMB life.

[21]  J. Schulz,et al.  Apoptotic mechanisms and antiapoptotic therapy in the MPTP model of Parkinson's disease. , 2003, Toxicology letters.

[22]  M. Smeyne,et al.  Method for culturing postnatal substantia nigra as an in vitro model of experimental Parkinson's disease. , 2002, Brain research. Brain research protocols.

[23]  T. Sherer,et al.  Animal models of Parkinson's disease. , 2002, BioEssays : news and reviews in molecular, cellular and developmental biology.

[24]  P. Mander,et al.  Involvement of inducible nitric oxide synthase in inflammation-induced dopaminergic neurodegeneration , 2002, Neuroscience.

[25]  S. Paul,et al.  Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[26]  M. Akbostancı,et al.  Visual evoked potentials in Parkinson's disease—correlation with clinical involvement , 2001, Clinical Neurology and Neurosurgery.

[27]  L. Marnett,et al.  4-hydroxynonenal induces apoptosis via caspase-3 activation and cytochrome c release. , 2001, Chemical research in toxicology.

[28]  T. Nabeshima,et al.  Amyloid β‐peptide induces nitric oxide production in rat hippocampus: association with cholinergic dysfunction and amelioration by inducible nitric oxide synthase inhibitors , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[29]  K. Castagnoli,et al.  Neuroprotection in the MPTP Parkinsonian C57BL/6 mouse model by a compound isolated from tobacco. , 2001, Chemical research in toxicology.

[30]  P. Kidd,et al.  Parkinson's disease as multifactorial oxidative neurodegeneration: implications for integrative management. , 2000, Alternative medicine review : a journal of clinical therapeutic.

[31]  M. Bach,et al.  Visual contrast response functions in Parkinson's disease: evidence from electroretinograms, visually evoked potentials and psychophysics , 2000, Clinical Neurophysiology.

[32]  M. Neal,et al.  Release of endogenous ascorbic acid preserves extracellular dopamine in the mammalian retina. , 1999, Investigative ophthalmology & visual science.

[33]  T. L. Krukoff.  Central actions of nitric oxide in regulation of autonomic functions , 1999, Brain Research Reviews.

[34]  V. O’Donnell,et al.  Nitric oxide inhibition of lipid peroxidation: kinetics of reaction with lipid peroxyl radicals and comparison with alpha-tocopherol. , 1997, Biochemistry.

[35]  H. Przuntek,et al.  Chromatic and achromatic visual evoked potentials in Parkinson's disease. , 1996, Electroencephalography and clinical neurophysiology.

[36]  T. Dawson,et al.  Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[37]  P. Emson,et al.  Immobilization-induced stress activates neuronal nitric oxide synthase (nNOS) mRNA and protein in hypothalamic-pituitary-adrenal axis in rats , 1996, Brain Research.

[38]  M. Neal,et al.  Nitric oxide inhibits depolarization-induced release of endogenous dopamine in the rabbit retina , 1995, Neuroscience Letters.

[39]  J. Obeso,et al.  Decreased tyrosine hydroxylase content in the dopaminergic neurons of MPTP–intoxicated monkeys: Effect of levodopa and GM1 ganglioside therapy , 1994, Annals of neurology.

[40]  J. Gutteridge,et al.  Biological origin of free radicals, and mechanisms of antioxidant protection. , 1994, Chemico-biological interactions.

[41]  O. Bugnon,et al.  Nitric oxide modulates endogenous dopamine release in bovine retina. , 1994, Neuroreport.

[42]  G. M. Strain,et al.  Flash and pattern reversal visual evoked potentials in C57BL/6J and B6CBAF1/J mice , 1993, Brain Research Bulletin.

[43]  A. Kalgutkar,et al.  Synthesis of novel MPTP analogs as potential monoamine oxidase B (MAO-B) inhibitors. , 1992, Journal of medicinal chemistry.

[44]  I. Date,et al.  Long-term effect of MPTP in the mouse brain in relation to aging: neurochemical and immunocytochemical analysis , 1990, Brain Research.

[45]  Baraboĭ Va.  The role of lipid peroxidation in the mechanism of stress , 1989 .

[46]  S Nightingale,et al.  Visual evoked cortical potentials and pattern electroretinograms in Parkinson's disease and control subjects. , 1986, Journal of neurology, neurosurgery, and psychiatry.

[47]  J. Lunec,et al.  LIPID PEROXIDATION AND PARKINSON'S DISEASE , 1986, The Lancet.

[48]  M. Yahr,et al.  Measurements of visual evoked potentials in Parkinson's disease. , 1978, Brain : a journal of neurology.

[49]  Gray Jg,et al.  LIVING AND DYING IN THE NINETEENTH CENTURY. , 1963 .

[50]  J. Kasahara,et al.  Neuropharmacological approach against MPTP (1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine)-induced mouse model of Parkinson's disease. , 2011, Acta neurobiologiae experimentalis.

[51]  T. Fujimura,et al.  Toxic effects of dopamine metabolism in Parkinson's disease. , 2009, Parkinsonism & related disorders.

[52]  G. Hacioglu,et al.  Visual evoked potentials in normal and sulfite oxidase deficient rats exposed to ingested sulfite. , 2006, Neurotoxicology.

[53]  P. Amouyel,et al.  Association between Parkinson's disease and polymorphisms in the nNOS and iNOS genes in a community-based case-control study. , 2003, Human molecular genetics.

[54]  N. Ogawa.  Dopamine neurotransmission and treatments for Parkinson's disease in the molecular biology era. , 1997, European neurology.

[55]  H. Tachibana,et al.  Visual Evoked Potentials (VEPs) in Parkinson's Disease: Correlation of Pattern VEPs Abnormality with Dementia , 1995, Alzheimer disease and associated disorders.

[56]  M. Rowan,et al.  Parkinson's dementia and Alzheimer's dementia: an evoked potential comparison. , 1993, Gerontology.

[57]  G. Celesia.  Evoked potential techniques in the evaluation of visual function. , 1984, Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society.